NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BTIG Downgrades Neogenomics (NEO) to Neutral
July 27, 2016 7:34 AM EDTBTIG downgraded Neogenomics (NASDAQ: NEO) from Buy to Neutral and removed its price target. Analyst Sean Lavin sees less compelling risk reward.
"Shares have risen 70% in less than a year. Our Buy thesis had been predicated on continued share gains, stable reimbursement, and... More
NeoGenomics (NEO) Tops Q2 EPS by 1c
July 26, 2016 8:18 AM EDTNeoGenomics (NASDAQ: NEO) reported Q2 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $63.1 million versus the consensus estimate of $61.07 million.
For earnings history and earnings-related data on NeoGenomics (NEO) click here.
... More